During the oral presentation “Cell Mimics As High Precision Controls for CGT Analytics and Potency Assays” Robyn Hall ... business generates asset-based fees, which are calculated as a ...

"We are excited to be entering into this collaboration with Synfini to accelerate drug discovery around a publicly available high-value target,” said Helena Mancebo, CEO of Multispan. "By using ...

Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...

Here, we expand the repertoire of PROTAC compatible E3 ligases by identifying a novel small molecule scaffold targeting the ubiquitin E3 ligase KLHDC2 using a fluorescence polarization-based high ...

A successful M&A outcome is contingent upon a deep understanding of the regulatory and scientific fundamentals that underpin ...

The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for ...

Orionis Biosciences, a privately held, clinical-stage life sciences company focused on the rational discovery and development of drug modalities with induced proximity mode of action, today announced ...

Cytokine secretion expression (IFN-γ and IL-2) were measured by an enzyme-linked immunosorbent assay ... T cells had increased specific killing ability compared to the control using VH-VL-based ...